Highlights
In a retrospective multiomic analysis of more than 3000 colorectal cancer samples, a distinct fibroblast population marked by collagen triple helix repeat containing 1 (CTHRC1) emerged as a clinically relevant stromal biomarker.
CTHRC1-positive cancer-associated fibroblasts (CAFs) were consistently associated with enhanced transforming growth factor-beta (TGF-beta) signaling, worse outcomes in early and advanced colorectal cancer, and a stromal program linked to treatment resistance.
The biomarker appeared useful across conventional molecular divisions. Both mismatch repair-deficient/microsatellite instability (dMMR/MSI) and mismatch repair-proficient/microsatellite stable (pMMR/MSS) tumors could be separated into immune-inflamed versus poorly immunogenic subtypes based on CTHRC1-positive CAF status.
Retrospective analyses of immunotherapy-treated cohorts suggested that CTHRC1-positive CAFs are associated with reduced benefit from immune checkpoint inhibitors in both MSI and MSS colorectal cancer, supporting exploration of TGF-beta-directed combination strategies.
Background and Clinical Need
Colorectal cancer (CRC) remains a major cause of cancer morbidity and mortality worldwide despite important gains in screening, surgery, adjuvant therapy, and systemic treatment. Clinically, one of the field’s persistent challenges is that tumors categorized similarly by stage or by broad molecular class can behave very differently. That inconsistency reflects, at least in part, marked intratumoral heterogeneity.
Current therapeutic stratification in CRC still relies heavily on clinicopathologic stage and a limited set of molecular biomarkers, including mismatch repair (MMR) or microsatellite instability (MSI) status, RAS and BRAF alterations, and HER2 amplification in selected patients. Among these, dMMR/MSI status has become particularly important because it predicts sensitivity to immune checkpoint inhibition. However, not all dMMR/MSI tumors derive durable benefit, and the far larger pMMR/MSS population generally remains poorly responsive to immunotherapy. This leaves a substantial unmet need for biomarkers that better capture the biology of immune exclusion and treatment resistance.
The tumor microenvironment, especially the stromal compartment, has increasingly been recognized as a determinant of prognosis and therapy response. Cancer-associated fibroblasts are not a uniform cell type; rather, they encompass multiple functional states that can shape extracellular matrix deposition, immune trafficking, growth factor signaling, and metastatic competence. In CRC, a practical biomarker that translates stromal biology into clinically deployable patient stratification has been lacking. The study by Iglesias Coma and colleagues addresses this gap by focusing on a CAF subset expressing CTHRC1.
Proposed Section Structure and Rationale
For this topic, the most logical clinical-scientific structure is: highlights; background and unmet need; study design and methods; key results; biologic interpretation and translational relevance; implications for pathology and treatment selection; limitations; and conclusion. This framework mirrors how clinicians assess biomarker studies: first understanding the problem, then the methods, the strength of the evidence, and finally whether the findings may alter practice.
Study Design and Methods
This was a multiomic, translational biomarker study integrating several complementary platforms. The investigators used single-cell RNA sequencing to resolve stromal heterogeneity, computational deconvolution to extend these observations into bulk tumor datasets, and protein-level evaluation in patient tumor samples to assess practical biomarker detectability. They also incorporated in vitro and in vivo preclinical models to explore biologic relevance.
The retrospective clinical component spanned more than 3000 patient samples across multiple cohorts, a notable strength because stromal signatures can be cohort-dependent if not tested broadly. According to the abstract, the authors analyzed both early-stage and advanced-stage disease and further examined several clinical trial datasets to explore the relationship between CTHRC1-positive CAFs and benefit from immune checkpoint inhibitors.
Although the abstract does not provide detailed cohort-by-cohort sample sizes, hazard ratios, confidence intervals, assay thresholds, or prespecified statistical plans, the overall design suggests a layered discovery-to-validation strategy: identify a stromal population at single-cell resolution, translate the signal to larger human cohorts, confirm at the protein level, and connect the biomarker to outcomes and therapeutic resistance.
Key Findings
CTHRC1 identifies a distinct fibroblast state in colorectal cancer
The central discovery is a subset of CAFs characterized by expression of CTHRC1. This is important because many prior stromal analyses have described fibroblast diversity without yielding markers that are sufficiently stable, measurable, and clinically interpretable for pathology workflows. By nominating CTHRC1 as a candidate protein-level marker, the study moves from descriptive stromal taxonomy toward a more actionable framework.
CTHRC1-positive CAFs were linked to increased TGF-beta signaling. This association is biologically plausible. TGF-beta is a canonical driver of fibroblast activation, extracellular matrix remodeling, immune exclusion, and epithelial-mesenchymal plasticity. A fibroblast state enriched for TGF-beta activity could therefore plausibly promote both aggressive disease behavior and resistance to immunotherapy.
Association with poor clinical outcomes across disease stages
The investigators report that CTHRC1-positive CAFs were associated with poor clinical outcomes in both early and advanced CRC. The abstract does not specify whether the endpoint was overall survival, disease-free survival, progression-free survival, or a composite measure in each cohort, nor does it provide effect sizes. That limits precise estimation of clinical magnitude. Even so, the consistency across disease stages is notable because it suggests that the stromal program is not merely a feature of late metastatic evolution but may be present earlier in tumor progression.
If validated prospectively, this could have several uses. In early-stage disease, a stromal biomarker might refine recurrence risk beyond standard histopathologic features. In advanced disease, it may help identify patients with a microenvironment less likely to respond to immunotherapy alone and perhaps more likely to require combination approaches.
Refining immunologic classification within both MSI and MSS disease
A particularly interesting finding is that CTHRC1-positive CAFs enabled stratification of both dMMR/MSI and pMMR/MSS tumors into immune-inflamed and poorly immunogenic subtypes. This is clinically relevant because current practice often treats MSI status as a broad surrogate for immunotherapy sensitivity. In reality, not all MSI tumors are equally inflamed or equally responsive.
The study’s framework suggests that stromal context modifies the immune phenotype even within molecularly defined groups. In dMMR/MSI tumors, CTHRC1-positive CAFs may identify a subset in which otherwise favorable neoantigenicity is counterbalanced by stromal-mediated immune suppression or exclusion. In pMMR/MSS disease, where immunotherapy responses are rare, the biomarker may help separate tumors with a particularly hostile stromal architecture from those with a comparatively more permissive immune milieu.
This concept is important because it shifts thinking from tumor-cell genomics alone to tumor ecology. A tumor may be immunogenic in principle yet functionally inaccessible to immune effectors if stromal barriers are dominant.
Association with reduced checkpoint inhibitor benefit
Retrospective analyses of several clinical trial cohorts suggested that CTHRC1-positive CAFs are linked to resistance to immune checkpoint inhibitors in both MSI and MSS CRC. Again, the abstract does not provide response rates, hazard ratios, or interaction statistics, so the strength of the predictive signal cannot yet be fully judged. It is also not clear whether the biomarker is independently predictive after accounting for tumor mutational load, T-cell infiltration, metastatic site, and line of therapy.
Nevertheless, the direction of effect fits a broader oncology literature in which stromal TGF-beta programs correlate with T-cell exclusion and reduced benefit from PD-1 or PD-L1 blockade. In CRC, where immunotherapy remains transformative for some MSI tumors but largely ineffective in MSS disease, a stromal biomarker that identifies immune-resistant biology would be clinically valuable.
Biologic Interpretation and Translational Relevance
The CTHRC1-positive CAF state appears to serve as both a marker and a potential mediator of an adverse stromal ecosystem. Several mechanisms may explain its clinical associations.
First, TGF-beta-rich stroma can remodel extracellular matrix architecture, producing a denser, more physically restrictive environment for immune cell trafficking. Second, activated fibroblasts may secrete chemokines and cytokines that preferentially recruit immunosuppressive cell populations or blunt cytotoxic lymphocyte function. Third, CAFs can alter antigen presentation indirectly through effects on myeloid cells and vascular organization. Finally, fibroblast-mediated matrix stiffness and paracrine signaling may support invasion and metastatic competence independent of immune effects.
These observations have direct translational implications. If CTHRC1-positive CAFs reliably mark TGF-beta-dominant, immunotherapy-resistant tumors, then biomarker-enriched trials combining checkpoint inhibition with TGF-beta pathway blockade become more rational. The study therefore supports not only a prognostic framework but also a therapeutic hypothesis.
Implications for Pathology and Clinical Practice
One of the more attractive features of this work is the proposed bridge between molecular profiling and routine diagnostic pathology. Single-cell data are powerful, but they are not currently practical for routine patient stratification. A biomarker that can be detected at the protein level in standard tumor specimens is far more realistic for clinical implementation.
For pathologists, CTHRC1 assessment could potentially complement standard MMR/MSI testing by adding stromal context. For oncologists, the combined interpretation might eventually look something like this: MSI status identifies baseline immunotherapy eligibility, while stromal CTHRC1 status refines expected benefit and may flag patients for combination strategies or clinical trials. In MSS disease, where effective immunotherapy biomarkers are sparse, a stromal classifier may be especially useful for identifying poor-prognosis, stroma-rich tumors.
That said, implementation should wait for prospective validation and assay standardization. Before incorporation into clinical workflows, laboratories would need clear scoring criteria, reproducibility data, and evidence that the marker adds value beyond existing clinicopathologic and molecular variables.
Strengths of the Study
The study has several notable strengths. It addresses a clinically important question in a tumor type where improved stratification is urgently needed. The multiomic design is well matched to the biologic complexity of stromal heterogeneity. The inclusion of more than 3000 patient samples across multiple cohorts supports robustness and reduces the risk that the observations are cohort-specific. Protein-level assessment improves translational feasibility, and the use of preclinical models adds biologic credibility to the proposed mechanism.
Another strength is the focus on both MSI and MSS disease rather than restricting the analysis to one molecular subtype. This broadens the relevance of the findings and aligns with real-world clinical decision-making.
Limitations and Cautions
Despite its promise, the study should be interpreted with appropriate caution. The analyses described in the abstract are retrospective. Retrospective biomarker studies are vulnerable to selection bias, variable specimen quality, inconsistent treatment exposure, and residual confounding.
The abstract also lacks key quantitative details necessary for critical appraisal: effect sizes, confidence intervals, calibration metrics, multivariable adjustments, predefined cutoffs, and information on assay reproducibility. Without these, it is difficult to determine whether CTHRC1 is primarily prognostic, truly predictive of immunotherapy benefit, or both.
Generalizability also remains to be established. Biomarker performance may differ by primary versus metastatic tissue, treatment line, metastatic site, and prior therapy exposure. Moreover, fibroblast states can be dynamic. A single biopsy may not fully capture temporal or spatial heterogeneity, especially in advanced disease.
Finally, therapeutic implications should not be overextended. While the data support investigation of TGF-beta blockade plus immunotherapy, they do not by themselves establish clinical efficacy for that combination in CTHRC1-positive CRC. Prospective, biomarker-stratified trials are needed.
Clinical Bottom Line
This study positions CTHRC1-positive CAFs as a potentially practical stromal biomarker that captures an aggressive, TGF-beta-associated tumor microenvironment in CRC. The biomarker appears to identify patients with worse outcomes and to refine immunologic stratification within both dMMR/MSI and pMMR/MSS disease. Most importantly, it may help explain why some ostensibly immunogenic tumors fail checkpoint blockade and why many MSS tumors remain refractory.
For clinicians, the immediate message is not to change practice today, but to watch this space closely. If prospectively validated, CTHRC1 testing could become part of a stroma-informed CRC classification system that complements tumor-cell molecular profiling and improves selection for immunotherapy-based combinations.
Funding and ClinicalTrials.gov
The abstract provided does not specify funding sources or ClinicalTrials.gov registration numbers. Because the work includes retrospective analyses and translational cohort studies rather than a single prospective interventional trial, a universal registration number may not apply. Readers should consult the full Gut publication for detailed funding disclosures and dataset provenance.
References
1. Iglesias Coma M, Badia-Ramentol J, Martinez-Ciarpaglini C, Linares J, Tarazona N, Mulet-Margalef N, Tornero-Piñero P, Sallent-Aragay A, Recort-Bascuas A, Gibert J, Sant-Albors M, Tauriello DVF, Cruz-Moral M, Carreras-Gallardo M, Sancho E, Morral Martinez C, Garrido M, Mozo JLM, Cervantes A, Montagut C, Batlle E, Calon A. Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. Gut. 2026-04-14. PMID: 41980760.
2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-2520.
3. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer. J Clin Oncol. 2017;35(8):773-779.
4. Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al. TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538-543.
5. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE 3rd, Koeppen H, Astarita JL, Cubas R, et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544-548.
